Da Volterra announces 20M€ from EIB to advance clinical development against antibiotic resistance

Da Volterra announces 20M€ from EIB to advance clinical development against antibiotic resistance


Back to news page

Da Volterra announces 20M€ from EIB to advance clinical development against antibiotic resistance

We are pleased to announce that the European Investment Bank (EIB) and our biopharmaceutical company, Da Volterra, have entered into a 20M€ financing agreement to support acceleration of the clinical development of Da Volterra’s innovative pipeline. More details may be found in the press release.

Press Release in English

Communiqué de Presse en Français